Skip to content

Poorly Soluble Drugs

Currently, about 40% of drug development candidates and approximately 70% of new drug leads have low aqueous solubility. Poor solubility creates drug delivery challenges such as erratic absorption and low oral bioavailability. CPES has a range of enabling technologies that can be used to design a formulation that will enhance the solubility of your active.

We can investigate a number of approaches:

  • Amorphous Forms
  • Co-crystals and novel polymorphs
  • Micronisation and Nanoprocessing
  • Complexation
  • Liposomes
  • Micelles
Placing vials in the freeze dryer